More sarcoma patients are beating the odds with pembrolizumab! This immunotherapy can change the treatment for limb sarcomas ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

As expected, serious adverse events were more frequent in the experimental group (56%) compared with the control group (31%), but there were no deaths related to treatment in either group. Importantly ...

Fecal microbiota transplantation has significantly improved progression-free survival in patients with metastatic renal cell ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...